[Abstract] [PDF] [HTML] [Linked
International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109
Volume 11, Issue 2, June 2014 pp 180-186
Clinical applications of mifepristone in obstetrics and gynaecology
Alka B. Patil1, G. Garima2
1Professor and HOD, 2Lecturer, Department of OBGY, A.C.P.M. Medical College Dhule, Maharashtra, INDIA.
Academic Editor: Dr. Aher K. R.
Roussel Uclaf in 1980 discovered Mifepristone. Mifepristone acts at the receptor level, binding strongly to the progesterone and glucocorticoid receptors, and to a lesser extent to the androgen receptors. Mifepristone is a potent antiprogesterone and antiglucocorticoid and a weak antiandrogen. Mifepristone is used for various conditions in Obstetrics and Gynaecology. Obstetrical indications include Medical abortion, second trimester abortion, cervical ripening, induction of labour. It has emerging role in emergency contraception and oestrogen-free contraception. Gynaecological indications are extended to medical management of fibroid and endometriosis. Due to antiglucocorticoid receptors present in ovarian cancer cells, Mifepristone can act as anticancer drug by virtue of its antiglucocorticoid activity. Other potential indications of Mifepristone and Gynaecology should be further developed. Here, we summarize the basic data and review related to its molecular and cellular mechanisms of action and its medical use.